A team of scientists led by renowned oncologist Mariano Barbacid at Spain’s National Cancer Research Centre (CNIO) has achieved a remarkable breakthrough in the fight against pancreatic cancer. Their pioneering research has resulted in a novel drug combination that led to the complete regression of KRAS-mutated pancreatic tumors in mice, offering new hope for one of the deadliest forms of cancer.
The Innovative Drug Combination The CNIO team’s therapy combines three targeted drugs:
- RMC-6236 (Daraxonrasib): A next-generation inhibitor that directly targets the mutated KRAS protein—a key driver in pancreatic cancer, found in over 90% of pancreatic ductal adenocarcinomas.
- Afatinib: An EGFR (Epidermal Growth Factor Receptor) inhibitor that blocks cellular signaling pathways responsible for tumor growth and progression.
- SD36: A STAT3 degrader that eliminates the STAT3 protein, which is involved in cancer cell survival and resistance to treatment.
Key Findings The new combination therapy led to complete tumor regression in mouse models, with no observed relapse. Notably, the treatment displayed minimal side effects, indicating a low toxicity profile—a crucial advantage over many existing cancer therapies. This success overcomes a major hurdle in pancreatic cancer treatment: resistance to KRAS-targeted therapies.
Scientific and Clinical Significance KRAS mutations are notoriously difficult to treat and are present in the vast majority of pancreatic cancers. Previous attempts to target KRAS have been hampered by drug resistance and toxicity. By simultaneously attacking KRAS, EGFR, and STAT3, this multi-pronged approach disrupts multiple pathways that tumors use to survive and evade treatment.
Implications and Future Prospects The promising results in preclinical models set the stage for future clinical trials, potentially paving the way for a new, more effective, and less toxic therapy for pancreatic cancer patients. The KRAS inhibitor RMC-6236 is already regarded as a promising candidate and may receive regulatory approval as early as late 2026 or early 2027.
Conclusion This breakthrough represents a significant advance in pancreatic cancer research, offering new optimism for patients facing this aggressive disease. As the research moves toward clinical trials, the medical community will watch closely, hopeful that this innovative therapy could revolutionize pancreatic cancer treatment worldwide.
